Lyell Immunopharma’s (LYEL) “Neutral” Rating Reiterated at HC Wainwright

Lyell Immunopharma (NASDAQ:LYEL)‘s stock had its “neutral” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday, June 24th, MarketBeat.com reports. They presently have a $10.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 8.87% from the company’s previous close.

Separately, Wall Street Zen raised shares of Lyell Immunopharma to a “hold” rating in a research note on Friday, June 6th.

Lyell Immunopharma Trading Up 3.9%

Shares of NASDAQ:LYEL traded up $0.35 during trading on Tuesday, reaching $9.19. 24,638 shares of the stock were exchanged, compared to its average volume of 71,957. Lyell Immunopharma has a 12 month low of $7.65 and a 12 month high of $38.40. The firm has a market cap of $136.03 million, a PE ratio of -0.37 and a beta of -0.26. The stock has a 50-day moving average price of $9.13 and a 200-day moving average price of $10.85.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($3.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.80) by $0.20. The business had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative return on equity of 73.66% and a negative net margin of 514,649.22%. On average, sell-side analysts expect that Lyell Immunopharma will post -0.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lyell Immunopharma

Institutional investors have recently added to or reduced their stakes in the stock. Graham Capital Management L.P. bought a new stake in shares of Lyell Immunopharma during the fourth quarter worth $33,000. RPO LLC bought a new stake in Lyell Immunopharma during the 4th quarter worth $42,000. Wells Fargo & Company MN raised its position in Lyell Immunopharma by 27.8% in the fourth quarter. Wells Fargo & Company MN now owns 94,320 shares of the company’s stock valued at $60,000 after purchasing an additional 20,542 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in shares of Lyell Immunopharma during the fourth quarter worth about $64,000. Finally, AQR Capital Management LLC increased its stake in shares of Lyell Immunopharma by 773.5% in the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock valued at $94,000 after buying an additional 154,327 shares during the period. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.